Cancer patients will miss out on exciting new treatments after NICE passed up a golden opportunity to ensure its evaluation methods support approval of the most innovative, potentially game-changing drugs.

Despite increasing numbers of cancer drugs being licensed, an analysis has found that highly innovative drugs took longer to reach NHS patients than more conventional treatments.

Over one-third of surviving cancer patients have received state-of-the-art targeted drug treatment or immunotherapy, reveals a new survey highlighting the ‘revolution’ in cancer treatment over the last decade.